These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 128411)

  • 1. Phase I study of thalicarpine (NAC-68075), a plant alkaloid of noval structure.
    Creaven PJ; Cohen MH; Selawry OS; Tejada F; Broder LE
    Cancer Chemother Rep; 1975; 59(5):1001-6. PubMed ID: 128411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An abbreviated phase II trial of thalicarpine.
    Leimert JT; Corder MP; Elliott TE; Lovett JM
    Cancer Treat Rep; 1980; 64(12):1389-90. PubMed ID: 6451289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
    Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
    Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of hycanthone.
    Legha SS; Grose WE; Bodey GP
    Cancer Treat Rep; 1978 Aug; 62(8):1173-6. PubMed ID: 356976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical evaluation of doxifluridine.
    Hurteloup P; Armand JP; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
    Cancer Treat Rep; 1986 Jun; 70(6):731-7. PubMed ID: 2942245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial clinical trials of maytansine, an antitumor plant alkaloid.
    Chabner BA; Levine AS; Johnson BL; Young RC
    Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
    Löffler TM; Freund W; Lipke J; Hausamen TU
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
    Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
    Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
    Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
    Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Eskens FA; Greim GA; van Zuylen C; Wolff I; Denis LJ; Planting AS; Muskiet FA; Wanders J; Barbet NC; Choi L; Capdeville R; Verweij J; Hanauske AR; Bruntsch U
    Clin Cancer Res; 2000 May; 6(5):1736-43. PubMed ID: 10815892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
    Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phase I trial of inosine dialdehyde (NSC-118994).
    Kaufman J; Mittelman A
    Cancer Chemother Rep; 1975; 59(5):1007-14. PubMed ID: 1106841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD; Raefsky EL; Greco FA
    Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
    Lokich JJ
    Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.